Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
Paying user area
Try for free
Allergan PLC pages available for free this week:
- Income Statement
- Balance Sheet: Assets
- Common-Size Balance Sheet: Assets
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Common Stock Valuation Ratios
- Present Value of Free Cash Flow to Equity (FCFE)
- Selected Financial Data since 2005
- Operating Profit Margin since 2005
- Price to Book Value (P/BV) since 2005
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Allergan PLC for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Allergan PLC, common-size consolidated balance sheet: liabilities and stockholders’ equity
Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).
- Accrued third-party rebates
- There is a consistent upward trend from 0.94% in 2015 to 2.11% in 2019, indicating increasing rebates liabilities relative to total liabilities and equity.
- Litigation-related reserves and legal fees
- These liabilities remain low and stable between 0.07% and 0.16% until 2018, then spike significantly to 1.32% in 2019, suggesting emerging or resolved legal matters impacting liability.
- Accrued payroll and related benefits
- A steady increase from 0.30% in 2015 to 0.88% in 2019 implies growing payroll-related obligations relative to the company's total liabilities and equity.
- Accrued returns and other allowances
- This component more than doubles from 0.21% in 2015 to 0.63% in 2019, indicating higher anticipated product returns or other allowances.
- Accrued R&D expenditures
- There is a decrease from 0.28% in 2015 to 0.12% in 2016, followed by slight fluctuations and a stable level near 0.20% in 2018-2019, suggesting relatively stable R&D accrual patterns in recent years.
- Interest payable
- This liability remains quite stable, fluctuating narrowly around 0.20% across the years, indicating consistent interest obligations relative to total liabilities and equity.
- Royalties payable
- There is an increase from 0.09% in 2015 to 0.23% in 2019, demonstrating growing royalty-related liabilities.
- Accrued pharmaceutical fees
- These fees remain relatively stable between 0.12% and 0.17%, with a slight downward trend toward 0.13% in 2019.
- Accrued severance, retention, and other shutdown costs
- The trend is downward, starting at 0.08% in 2015 and diminishing to 0.01% in 2019, possibly reflecting reduced restructuring activities.
- Accrued non-provision taxes
- Values are low and stable around 0.07% across the periods, indicating consistent tax accruals without significant changes.
- Accrued selling and marketing expenditures
- There is a decrease from 0.09% in 2015 to 0.04% in 2017, stabilizing at 0.06% subsequently, suggesting relative control over selling and marketing expenses accrued.
- Current portion of contingent consideration obligations
- This fluctuates significantly, peaking at 0.40% in 2016, then declining to 0.01% in 2018-2019. This pattern may indicate settlement or revaluation of contingent liabilities over time.
- Dividends payable
- Dividends payable disappear after 2017, with zero values recorded in 2018 and 2019, which could suggest a change in dividend policy or timing.
- Other accrued expenses
- There is a sharp increase to 1.01% in 2017 from 0.27% in 2015, followed by a decrease to 0.43% in 2019, indicating some volatility in miscellaneous accrued expenses.
- Accrued expenses
- Overall, accrued expenses rise steadily from 2.93% in 2015 to 6.29% in 2019, reflecting growing short-term liabilities relative to total liabilities and equity.
- Accounts payable
- This item fluctuates, decreasing in 2016 to 0.17%, then increasing to 0.41% by 2019, showing variability in payables management or trading terms.
- Accounts payable and accrued expenses
- A consistent upward trend is observed, growing from 3.20% in 2015 to 6.70% in 2019, reinforcing the increase seen in accrued expenses and accounts payable combined.
- Income taxes payable
- Slight increases are noted, moving from 0.04% in 2015 to 0.07% by 2018 and 2019, showing modest growth in tax liabilities.
- Current portion of long-term debt and capital leases
- This line increases overall from 1.79% in 2015 to 4.79% in 2019, with a dip in 2018. The rise indicates increasing short-term debt obligations or reclassification of debt portions.
- Current portion of lease liability, operating
- Data is only available for 2019 at 0.13%, indicating a new lease liability item likely introduced due to accounting changes.
- Current liabilities held for sale
- Present only in 2015 at 1.10%, implying a one-time classification of liabilities related to assets held for sale that disappears afterward.
- Current liabilities (total)
- The ratio shows a decrease from 6.13% in 2015 to 5.63% in 2018, then markedly increases to 11.69% in 2019, indicating a substantial increase in short-term obligations in the latest year.
- Long-term debt and capital leases, excluding current portion
- There is a declining trend from 29.66% in 2015 to 19.13% in 2019, suggesting a reduction in long-term debt relative to total liabilities and equity.
- Lease liability, operating, excluding current portion
- Reported only in 2019 at 0.47%, evidencing new recognition of lease liabilities potentially due to updated accounting standards.
- Acquisition related contingent consideration liabilities
- These liabilities decline from 0.58% in 2015 to 0.33% in 2018, then slightly increase to 0.40% in 2019, indicating some fluctuation in contingent obligations tied to acquisitions.
- Long-term pension and post-retirement liability
- Relatively stable near 0.15%, with minimal variation, suggesting consistent valuation and funding of pension obligations.
- Legacy Allergan deferred executive compensation
- This liability remains steady at approximately 0.09%-0.10%, signaling stable deferred compensation obligations.
- Accrued R&D milestone
- Identified only from 2018 onwards at around 0.07%-0.08%, showing recognition of accruals linked to R&D milestones achieved or expected.
- Long-term contractual obligations
- Small values between 0.02% and 0.04% are recorded, indicating minor long-term contractual liabilities relative to total liabilities and equity.
- Deferred revenue
- A slight increase is seen from 0.01% in 2015 to 0.04% in 2018, then a small decline to 0.03% in 2019, demonstrating relatively minor but consistent deferred revenue accruals.
- Product warranties
- Stable at around 0.02%-0.03%, indicating a regular provision for warranty-related liability.
- Long-term severance and restructuring liabilities
- These liabilities are minimal and variable, remaining below 0.04% and decreasing to 0.01% by 2019, reflecting limited restructuring obligations.
- Other long-term liabilities
- Reported twice with differing values: one set between 0.02% to 0.09%, another between 0.75% and 0.93%. Both sets show minor fluctuations, collectively suggesting small miscellaneous long-term liabilities.
- Long-term liabilities held for sale
- Only present in 2015 at 0.43%, indicating a one-time event of liabilities classified as held for sale.
- Other taxes payable
- There is a clear rising trend from 0.59% in 2015 to 1.80% in 2019, suggesting increasing tax-related liabilities outside of income taxes.
- Deferred tax liabilities
- Peaking at 10.05% in 2016 before declining steadily to 4.61% in 2019, indicating a significant reduction in deferred tax obligations after 2016.
- Long-term liabilities (total)
- This figure decreases from 37.49% in 2015 to 26.86% in 2019, reflecting an overall reduction in long-term obligations relative to total liabilities and equity.
- Total liabilities
- Total liabilities decrease from 43.62% in 2015 to 36.01% in 2018 before increasing to 38.55% in 2019, showing an overall declining trend with a slight reversal in the latest year.
- Preferred shares
- The percentage increases slightly from 3.63% in 2015 to 4.17% in 2017, then data is absent for subsequent years, suggesting possible redemption or reclassification after 2017.
- Additional paid-in capital
- A decline from 50.43% in 2015 to 41.83% in 2016 is followed by a steady increase reaching 59.11% in 2019, indicating growth in paid-in capital over time.
- Retained earnings
- Significant fluctuation occurs with a peak at 14.22% in 2016, followed by a steep decrease to 1.05% in 2019, suggesting variability in profit retention and dividend policies.
- Accumulated other comprehensive income (loss)
- This item moves from negative values in 2015 and 2016 to positive amounts from 2017 onward, stabilizing around 1.27%, indicating improved comprehensive income excluding net earnings.
- Shareholders’ equity
- There is a growth trend from 56.38% in 2015 to a peak of 63.97% in 2018, with a slight decline to 61.43% in 2019, indicating an overall strengthening of equity relative to total liabilities and equity.
- Noncontrolling interest
- Remains negligible but slightly positive from 2016 onward, suggesting minimal ownership stakes by outside parties.
- Total equity
- Follows a similar pattern to shareholders’ equity, increasing from 56.38% in 2015 to 63.99% in 2018, and then declining slightly to 61.45% in 2019.
- Total liabilities and equity
- Consistently at 100% by definition, serving as the base for all other percentage analyses.